[
  {
    "id": "orf_api_dependency_01",
    "source": "ORF - Time to end the battle of Indian pharmaceutical players and Chinese key ingredients",
    "source_url": "https://www.orfonline.org/expert-speak/time-to-end-the-battle-of-indian-pharmaceutical-players-and-chinese-key-ingredients",
    "text": "ORF notes that India's formulation strength still sits on top of heavy bulk-drug and API dependence on China, with import exposure often cited in the 65-70% range. That concentration leaves Indian supply vulnerable to price spikes and sudden export or production shocks.",
    "keywords": ["dependency", "API", "China", "import", "vulnerability"]
  },
  {
    "id": "orf_pharma_cluster_02",
    "source": "ORF - Understanding the coming challenges to India's pharma sector",
    "source_url": "https://www.orfonline.org/expert-speak/understanding-the-coming-challenges-to-indias-pharma-sector-66556",
    "text": "ORF highlights that major Chinese raw-material clusters such as Hubei, Zhejiang and Jiangsu are deeply tied to global pharmaceutical supply. Disruption in those manufacturing centres can quickly tighten API availability for Indian producers.",
    "keywords": ["cluster", "Hubei", "Zhejiang", "Jiangsu", "API", "supply shock"]
  },
  {
    "id": "orf_trade_security_03",
    "source": "ORF - Tariffs and Health Security: The Future of US-India Pharma Trade",
    "source_url": "https://www.orfonline.org/expert-speak/tariffs-and-health-security-the-future-of-us-india-pharma-trade",
    "text": "ORF argues that India still imports a large share of its API requirement from China and that trade or production disruptions can undermine health security. The case for de-risking depends on diversifying KSM and API sourcing before the next shock hits.",
    "keywords": ["health security", "API", "trade", "de-risking", "China"]
  },
  {
    "id": "nlem_2022_01",
    "source": "CDSCO - Essential Medicines",
    "source_url": "https://cdsco.gov.in/opencms/opencms/en/consumer/Essential-Medicines/",
    "text": "The National List of Essential Medicines is meant to support continuous availability of priority medicines in functioning health systems. Tier 1 medicines should be prioritized for monitoring because stockouts have broad and immediate public-health effects.",
    "keywords": ["NLEM", "essential medicines", "availability", "public health", "tier 1"]
  },
  {
    "id": "nlem_2022_02",
    "source": "CDSCO - National List of Essential Medicines 2022",
    "source_url": "https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/nlem2022.pdf",
    "text": "NLEM 2022 covers both widely used medicines and specialized therapies where failure of supply still harms care delivery for specific patient groups. Buffer policies and procurement planning should account for Tier 2 and Tier 3 exposure as well, not just the highest-volume products.",
    "keywords": ["NLEM", "tier 2", "tier 3", "buffer stock", "procurement"]
  },
  {
    "id": "niti_pli_01",
    "source": "NITI Aayog - Public Finance and Policy Analysis Division",
    "source_url": "https://niti.gov.in/divisions/division/public-finance-and-policy-analysis",
    "text": "NITI Aayog states that it helped shape the contours of the Production Linked Incentive schemes for active pharmaceutical ingredients and other strategic sectors. The policy direction is to build domestic capacity in inputs that create national import vulnerability.",
    "keywords": ["NITI Aayog", "PLI", "API", "domestic manufacturing", "capacity"]
  },
  {
    "id": "who_eml_01",
    "source": "WHO Model List of Essential Medicines - 23rd list, 2023",
    "source_url": "https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02",
    "text": "WHO states that essential medicines should be available in functioning health systems at all times, in the right dosage forms, with assured quality and affordable pricing. That makes supply continuity a core operational requirement rather than a policy afterthought.",
    "keywords": ["WHO", "EML", "essential medicines", "availability", "stockouts"]
  },
  {
    "id": "fda_shortage_01",
    "source": "FDA Drug Shortages Database",
    "source_url": "https://www.accessdata.fda.gov/scripts/drugshortages/",
    "text": "The FDA describes shortages as situations where supply does not meet current or projected demand, often driven by manufacturing quality problems, raw-material delays, or sudden demand changes. Drugs with no therapeutic substitute require tighter monitoring and earlier escalation.",
    "keywords": ["FDA", "shortage", "manufacturing", "raw materials", "substitute"]
  },
  {
    "id": "dop_pli_01",
    "source": "Department of Pharmaceuticals - PLI Scheme for Bulk Drugs Guidelines",
    "source_url": "https://pharmaceuticals.gov.in/sites/default/files/Guidelines%20for%20the%20Production%20Linked%20Incentive%20%28PLI%29%20Scheme%20for%20promotion%20of_0.pdf",
    "text": "The Department of Pharmaceuticals says uninterrupted supply of quality bulk drugs is critical for drug security and explicitly frames reduction of import dependence in KSMs, drug intermediates, and APIs as a core objective of the PLI scheme for bulk drugs.",
    "keywords": ["DoP", "PLI", "bulk drugs", "KSM", "API", "import dependence"]
  },
  {
    "id": "dop_api_ksm_02",
    "source": "Department of Pharmaceuticals - Bulk Drug Parks Guidelines",
    "source_url": "https://pharmaceuticals.gov.in/sites/default/files/Guidelines%20of%20the%20Scheme%20Promotion%20of%20Bulk%20Drug%20Parks.pdf",
    "text": "The Bulk Drug Parks guidelines define an API as a substance used in manufacturing that becomes the active ingredient of the final drug, and position KSM and intermediate production as core infrastructure targets. That makes upstream input visibility essential for early-warning systems.",
    "keywords": ["API", "KSM", "bulk drug park", "intermediates", "definitions"]
  }
]